Atidarsagene autotemcel for metachromatic leukodystrophy
J Manag Care Spec Pharm
.
2024 Feb 3;30(2):201-205.
doi: 10.18553/jmcp.2024.30.2.201.
Authors
Shahariar Mohammed Fahim
1
,
Grace Lin
1
2
,
Kangho Suh
3
,
Josh J Carlson
4
,
Marina Richardson
1
,
Belen Herce-Hagiwara
1
,
Ronald Dickerson
4
,
Steven D Pearson
1
,
David M Rind
1
,
Foluso Agboola
1
Affiliations
1
Institute for Clinical and Economic Review, Boston, Massachusetts.
2
Division of General Internal Medicine and Philip R. Lee Institute for Health Policy Studies, University of California San Francisco.
3
School of Pharmacy, University of Pittsburgh, Pennsylvania.
4
Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.
PMID:
38308621
PMCID:
PMC10838137
DOI:
10.18553/jmcp.2024.30.2.201
No abstract available
MeSH terms
Genetic Therapy*
Humans
Leukodystrophy, Metachromatic* / therapy